

## Supplementary Data

SUPPLEMENTARY TABLE S1. PATIENT CHARACTERISTICS

<i>Characteristic</i>	<i>NR</i> (n=21)	<i>SVR</i> (n=21)	<i>p</i> <i>value</i>
Age	46 ± 8	45 ± 6	>0.05
Male gender	17 (81)	20 (95)	>0.05
Black	16 (76)	8 (43)	>0.05
CD4 <sup>+</sup> T cells/cm <sup>3</sup>	518 ± 303/26 ± 9	564 ± 296/30 ± 9	>0.05
HIV VL (log) copies/ml	2.01 ± 0.6	2.26 ± 0.9	>0.05
HCV VL (log) IU/ml	6.29 ± 0.4	5.64 ± 1.0	>0.05
HCV genotype 1	19 (90)	16 (76)	>0.05

Descriptive statistics are mean (SD) OR number (%).

Forty-two hepatitis C virus (HCV)/HIV-coinfected patients with known treatment outcomes after standard PEG-interferon (IFN)- $\alpha$ /ribavirin (RBV) therapy were included in this study.

NR, nonresponders; SD, standard deviation; SVR, sustained virologic response; VL, viral load.